Pharmacovigilance

Pharmacovigilance encompasses the detection, assessment, understanding, and prevention of adverse effects and other medicine-related problems. Its role is expanding as regulators, healthcare systems, manufacturers, and patients seek earlier identification of safety signals across clinical development, approval, and real-world use. The field increasingly combines structured safety reporting with electronic health records, claims data, registries, literature, and patient-generated information.

Pharmacovigilance is shifting from largely periodic, case-based review toward continuous, data-linked surveillance. Greater use of electronic submissions, standardized data models, automated case intake, and real-world evidence is improving traceability and enabling safety teams to evaluate medicines across more diverse populations and care settings. These changes also increase expectations for data quality, explainability, privacy protection, and consistent regulatory compliance across jurisdictions.

Artificial intelligence can support duplicate detection, case triage, natural-language extraction, coding assistance, literature screening, and prioritization of potential safety signals. Its cumulative value depends on validated workflows, representative training data, human oversight, and auditable decision paths. Pharmacovigilance organizations must manage risks involving bias, hallucinated outputs, model drift, cybersecurity, patient confidentiality, and the difficulty of explaining automated recommendations to regulators and clinical stakeholders.

North America emphasizes mature reporting infrastructure, risk-management obligations, and integration of real-world data. Europe combines extensive cross-border coordination with strong privacy, transparency, and patient-safety requirements. Asia-Pacific is characterized by expanding regulatory capacity, large and diverse patient populations, and growing digital-health adoption. Latin America continues to strengthen national surveillance systems and harmonization efforts. The Middle East is developing pharmacovigilance capabilities alongside healthcare modernization, while Africa faces uneven reporting coverage and infrastructure but has substantial opportunity to improve surveillance through mobile tools, regional collaboration, and capacity building.

ASEAN’s diverse regulatory systems make regional alignment, shared terminology, and interoperable reporting especially important. BRICS members reflect varied healthcare infrastructures and regulatory models, creating opportunities for collaborative evidence generation while requiring careful attention to comparability. The European Union relies on coordinated medicines oversight and common safety processes. G7 countries generally operate advanced surveillance environments with high expectations for data integrity and transparency. GCC states are strengthening cooperation across connected health systems, and NATO members illustrate the importance of resilient medicine-safety processes during emergencies and supply disruptions.

Australia and Canada continue to emphasize structured reporting, regulatory coordination, and real-world safety evidence. Brazil and Mexico are advancing national surveillance while addressing reporting consistency across decentralized health systems. China and India are expanding digital health and regulatory capabilities amid large, heterogeneous populations. Japan and South Korea combine sophisticated healthcare data environments with strong post-market oversight. France, Germany, Italy, Spain, and the United Kingdom operate within mature European pharmacovigilance frameworks, while also adapting to digital evidence and evolving privacy expectations. Russia’s surveillance environment reflects the importance of national reporting capacity, data governance, and continuity of safety monitoring.

Industry leaders should establish end-to-end data governance covering provenance, validation, access controls, retention, and auditability. They should deploy automation selectively, beginning with high-volume and well-defined activities while retaining qualified human review for clinical judgment and regulatory decisions. Organizations should strengthen patient and healthcare-professional reporting, connect complementary real-world data sources, test systems across demographic groups, and maintain documented model-validation procedures. Cross-border operating models should align global standards with local reporting obligations, and preparedness plans should address product quality events, shortages, public-health emergencies, and cyber incidents.

This executive summary applies a structured review of pharmacovigilance concepts, regulatory expectations, digital-health developments, artificial-intelligence applications, and publicly documented regional and national operating conditions. Findings are synthesized thematically across technology, governance, data quality, workforce, and regulatory coordination. The analysis avoids unsupported numerical claims and distinguishes broadly documented industry practices from jurisdiction-specific considerations. Because pharmacovigilance requirements evolve, conclusions should be validated against current legislation, regulator guidance, and local reporting procedures before operational use.

Pharmacovigilance is becoming more continuous, data-intensive, and technology-enabled, but better tools alone do not guarantee better safety outcomes. Sustainable progress depends on reliable reporting, interoperable data, skilled review, transparent governance, and meaningful collaboration among regulators, healthcare professionals, patients, and industry. Organizations that combine responsible artificial intelligence with strong scientific and compliance controls will be better positioned to identify emerging risks and support safer medicine use across diverse populations.